Date	Price Target	Rating	Analyst
6/13/2024	$6.00 → $1.00	Buy → Hold	Stifel
6/13/2024	$10.00 → $1.00	Buy → Hold	Canaccord Genuity
6/13/2024		Buy → Hold	Needham
6/13/2024		Buy → Neutral	H.C. Wainwright
3/8/2023	$13.00 → $6.00	Neutral → Underperform	BofA Securities
3/8/2022	$17.00 → $20.00	Neutral → Overweight	JP Morgan
11/1/2021	$33.00	Buy	Canaccord Genuity
8/24/2021	$33.00 → $35.00	Buy	HC Wainwright & Co.

More analyst ratings

Cannabis Stock Gainers And Losers From July 24, 2024
GAINERS: Global Hemp Group (OTC:GBHPF) shares closed up 117.39% at $0.04 CordovaCann (OTC:LVRLF) shares closed up 19.90% at $0.06 SOL Glb Inv (OTC:SOLCF) shares closed up 19.40% at $0.06 1933 Industries (OTC:TGIFF) shares closed up 11.81% at $0.01 Global Compliance (OTC:FUAPF) shares closed up 10.37% at $0.00 CLS Holdings USA (OTC:CLSH) shares closed up 6.01% at $0.04 22nd Century Group (NASDAQ:XXII) shares closed up 4.77% at $0.72 EnWave (OTC:NWVCF) shares closed up 4.53% at $0.17 Psychemedics (NASDAQ:PMD) shares closed up 3.52% at $2.24 cbdMD (AMEX:YCBD) shares closed up 3.11% at $0.63 LOSERS: Green Growth Brands (OTC:GGBXF) shares closed down 99.00% at $1e-06 Leafbuyer Techs (OTC:LBUY)
7/24/24 4:30:05 PM ET
$ACB
$CARA
$CGC
$CRON
Medicinal Chemicals and Botanical Products
Health Care
Biotechnology: Pharmaceutical Preparations
RETAIL: Building Materials
Bullish Sentiment Across The Cannabis Space - Check Full Movers For July 16, 2024
GAINERS: Pharmadrug (OTC:LMLLF) shares closed up 85.78% at $0.01 Heritage Cannabis Holding (OTC:HERTF) shares closed up 66.67% at $0.001 Cann Gr (OTC:CNGGF) shares closed up 37.93% at $0.02 4Front Ventures (OTC:FFNTF) shares closed up 27.16% at $0.10 Elixinol Wellness (OTC:ELLXF) shares closed up 25.00% at $0.00 Kaya Holdings (OTC:KAYS) shares closed up 22.97% at $0.04 CNBX Pharmaceuticals (OTC:CNBX) shares closed up 17.19% at $0.01 Body and Mind (OTC:BMMJ) shares closed up 12.02% at $0.03 Cansortium (OTC:CNTMF) shares closed up 10.62% at $0.12 Cara Therapeutics (NASDAQ:CARA) shares closed up 10.45% at $0.37 Auxly Cannabis Group (OTC:CBWTF) shares closed up 8.56% at $0.03 Scotts Miracle Gro
7/16/24 4:30:05 PM ET
$CARA
$GRWG
$SMG
$UGRO
Biotechnology: Pharmaceutical Preparations
Health Care
RETAIL: Building Materials
Consumer Discretionary
Cannabis Stock Gainers And Losers From July 15, 2024
GAINERS: Australis Capital (OTC:AUSAF) shares closed up 9900.00% at $0.01 Global Hemp Group (OTC:GBHPF) shares closed up 70.36% at $0.05 Maple Leaf Green World (OTC:MGWFF) shares closed up 68.48% at $0.05 CordovaCann (OTC:LVRLF) shares closed up 42.50% at $0.06 Target Group (OTC:CBDY) shares closed up 25.00% at $0.00 Blueberries Medical (OTC:BBRRF) shares closed up 19.09% at $0.01 CLS Holdings USA (OTC:CLSH) shares closed up 17.00% at $0.04 Zelira Therapeutics (OTC:ZLDAF) shares closed up 15.32% at $0.55 Leafbuyer Techs (OTC:LBUY) shares closed up 14.67% at $0.02 Canopy Gwth (NASDAQ:CGC) shares closed up 10.92% at $7.14 SOL Glb Inv (OTC:SOLCF) shares closed up 10.66% at $0.05 Cansortium (OT
7/15/24 4:30:05 PM ET
$CARA
$CGC
$EAST
$GENE
Biotechnology: Pharmaceutical Preparations
Health Care
Medicinal Chemicals and Botanical Products
Beverages (Production/Distribution)

$CARA
Press Releases

Fastest customizable press release news feed in the world

Cara Therapeutics Announces Exploration of Strategic Alternatives
STAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced that it has engaged Piper Sandler & Co. to act as its financial advisor for the process of exploring and reviewing strategic alternatives. "We are committed to evaluating a range of strategic options to maximize value for our shareholders," said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. "As part of this effort, our Board of Directors has approved a streamlined operating plan focused on cost-containment and cash conservation." There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or
7/11/24 7:00:00 AM ET
$CARA
Biotechnology: Pharmaceutical Preparations
Health Care
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with notalgia paresthetica (NP). Oral difelikefalin did not demonstrate a meaningful clinical benefit at
6/12/24 4:01:00 PM ET
$CARA
Biotechnology: Pharmaceutical Preparations
Health Care
Cara Therapeutics Reports First Quarter 2024 Financial Results
STAMFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2024. "Our notalgia paresthetica (NP) pivotal clinical program is progressing ahead of schedule and we now expect to report topline efficacy and safety results from KOURAGE 1 Part A by the end of the second quarter of 2024," said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. "We believe the medical dermatology community's intere
5/13/24 4:01:00 PM ET
$CARA
Biotechnology: Pharmaceutical Preparations
Health Care

$CARA
Financials

Live finance-specific insights

Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
–Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of schedule; topline efficacy and safety results now expected in 3Q24– –Extended cash runway into 2026 with clinical prioritization strategy and reduction in force– –Conference call today at 4:30 p.m. EST– STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operatio
3/4/24 4:01:00 PM ET
$CARA
Biotechnology: Pharmaceutical Preparations
Health Care
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under "Events & Presentations" in the Investors section of the Company's website at www.CaraTherapeutics.com. About Cara Therapeutics Cara Therapeutics is a commercial-stage biopharmaceutical co
2/12/24 4:01:00 PM ET
$CARA
Biotechnology: Pharmaceutical Preparations
Health Care
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
– Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need – – Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued – – Planned workforce reduction of up to 50% – – Cara ended 2023 with approximately $101 million in cash; runway extended into 2026 – – Company to host conference call and webcast today at 8:30 a.m. EST – STAMFORD, Conn., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its operating expenses. These measures will extend the
1/22/24 7:00:00 AM ET
$CARA
Biotechnology: Pharmaceutical Preparations
Health Care

$CARA
Leadership Updates

Live Leadership Updates

Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors
STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Helen M. Boudreau to its Board of Directors. Ms. Boudreau has more than 30 years of operating experience in a variety of industries, including the biotechnology and pharmaceutical sectors, in addition to serving as a director on numerous public boards. "We are pleased to welcome Helen to the Cara board," said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics. "We look forward to leveraging her
8/3/23 7:00:00 AM ET
$CARA
Biotechnology: Pharmaceutical Preparations
Health Care
KemPharm Announces Appointment of Christopher Posner as New Independent Director
24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm's Board of Directors CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced the appointment of Christopher Posner to serve on the Company's Board of Directors. Mr. Posner is currently the president and CEO of Cara Therapeutics (NASDAQ:CARA), a commercial-stage biopharmaceutical company.
11/29/22 7:30:00 AM ET
$CARA
$KMPH
Biotechnology: Pharmaceutical Preparations
Health Care
Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors
STAMFORD, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Lisa von Moltke, M.D., to its Board of Directors. Dr. von Moltke currently serves as Executive Vice President and Chief Medical Officer at Seres Therapeutics, Inc. "We are very pleased to welcome Lisa to our board of directors," said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics. "Her extensive clinical development and pharmacology expertise will be of great value as we continue executing o
11/3/22 7:00:00 AM ET
$CARA
Biotechnology: Pharmaceutical Preparations
Health Care

FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

Products on NDA 214916

Approval Date(s) and History, Letters, Labels, Reviews for NDA 214916

Original Approvals or Tentative Approvals

Therapeutic Equivalents for NDA 214916

KORSUVA

Chat with this insight

Recent Analyst Ratings for $CARA

$CARA Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D filed by Cara Therapeutics Inc.

SEC Form SC 13G/A filed by Cara Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Cara Therapeutics Inc. (Amendment)

$CARA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cara Therapeutics downgraded by Stifel with a new price target

Cara Therapeutics downgraded by Canaccord Genuity with a new price target

Cara Therapeutics downgraded by Needham

$CARA FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

$CARA Market Insights

Live Market Insights

Cannabis Stock Gainers And Losers From July 24, 2024

Bullish Sentiment Across The Cannabis Space - Check Full Movers For July 16, 2024

Cannabis Stock Gainers And Losers From July 15, 2024

$CARA SEC Filings

SEC Form 10-Q filed by Cara Therapeutics Inc.

SEC Form 10-Q filed by Cara Therapeutics Inc.

SEC Form 8-K filed by Cara Therapeutics Inc.

$CARA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

PRESIDENT AND CEO Posner Christopher sold $1,064 worth of shares (3,668 units at $0.29), decreasing direct ownership by 2% to 168,768 units (SEC Form 4)

PRESIDENT AND CEO Posner Christopher sold $1,452 worth of shares (4,149 units at $0.35), decreasing direct ownership by 2% to 172,436 units (SEC Form 4)

Boudreau Helen M was granted 150,647 shares (SEC Form 4)

$CARA Press Releases

Fastest customizable press release news feed in the world

Cara Therapeutics Announces Exploration of Strategic Alternatives

Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica

Cara Therapeutics Reports First Quarter 2024 Financial Results

$CARA Financials

Live finance-specific insights

Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026

$CARA Leadership Updates

Live Leadership Updates

Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors

KemPharm Announces Appointment of Christopher Posner as New Independent Director

Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors

Recent Analyst Ratings for
$CARA

$CARA
Large Ownership Changes

$CARA
Analyst Ratings

$CARA
FDA approvals

$CARA
Market Insights

$CARA
SEC Filings

$CARA
Insider Trading

$CARA
Press Releases

$CARA
Financials

$CARA
Leadership Updates